4.5 Article

To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority

期刊

ACS INFECTIOUS DISEASES
卷 7, 期 8, 页码 2029-2042

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.0c00681

关键词

antimicrobial resistance; global health policy; market failure; push and pull incentives; access; One Health

资金

  1. Wellcome Trust ISSF award [204909/Z/16/Z]
  2. GCRF One Health Poultry Hub [BB/S011269/1]
  3. MRC at the Institute of Development Studies [MR/S013598/1]
  4. BBSRC [BB/S011269/1] Funding Source: UKRI
  5. MRC [MR/S013598/1] Funding Source: UKRI

向作者/读者索取更多资源

The COVID-19 pandemic has highlighted the dangers of infectious diseases globally, impacting both global health and the world economy. However, the even greater long-term danger of antimicrobial resistance in pathogenic bacteria and fungi is still under-appreciated. There is a critical need for governments to incentivize the development of antimicrobials to address this significant global challenge.
The COVID-19 pandemic has refocused attention worldwide on the dangers of infectious diseases, in terms of both global health and the effects on the world economy. Even in high income countries, health systems have been found wanting in dealing with the new infectious agent. However, the even greater long-term danger of antimicrobial resistance in pathogenic bacteria and fungi is still under-appreciated, especially among the general public. Although antimicrobial drug development faces significant scientific challenges, the gravest challenge at the moment appears to be economic, where the lack of a viable market has led to a collapse in drug development pipelines. There is therefore a critical need for governments across the world to further incentivize the development of antimicrobials. Most incentive strategies over the past decade have focused on so-called push incentives that bridge the costs of antimicrobial research and development, but these have been insufficient for reviving the pipeline. In this Perspective, we analyze the current incentive strategies in place for antimicrobial drug development, and focus on pull incentives, which instead aim to improve revenue generation and thereby resolve the antimicrobial market failure challenge. We further analyze these incentives in a broader One Health context and stress the importance of developing and enforcing strict protocols to ensure appropriate manufacturing practices and responsible use. Our analysis reiterates the importance of international cooperation, coordination across antimicrobial research, and sustained funding in tackling this significant global challenge. A failure to invest wisely and continuously to incentivize antimicrobial pipelines will have catastrophic consequences for global health and wellbeing in the years to come.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据